AstraZeneca chief executive David Brennan announced on Thursday that he would retire in June, just as earnings dropped. He departs, in the words of Bernstein analyst Tim Anderson, “at the exact moment that the financial wheels seem to be falling off.” Nexium (heartburn) and Seroquel (mental illness) are now losing patent protection; the big-selling cholesterol drug Crestor follows in 2016.
